Divis Laboratories Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Divis Laboratories Ltd filed with BSE on 06 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Divi's Laboratories reported consolidated total income of ₹3,144 crores for Q1 FY27 compared to ₹2,529 crores a year earlier, with profit after tax at ₹902 crores versus ₹545 crores in the same period last year. Management said standalone revenue grew 10% on a constant currency basis, with Custom Synthesis contributing 60% of revenue and Generics 40%. Management also discussed elevated solvent costs, a three-month rolling inventory strategy to secure supply, and progress on validation batches across peptide, generic and custom synthesis projects.
Numbers mentioned
Consolidated total income: ₹3,144 crores (Q1 FY27)
p. 6
“the Company reported a consolidated total income of ₹3,144 crores compared to ₹2,529 croresin the corresponding quarter of previous financial year”
Nilima Prasad Divi, page 6 of the filed PDF · View the filing
Consolidated profit after tax: ₹902 crores (Q1 FY27)
p. 6
“profit after tax stood at ₹902 crores compared with ₹545 crores in the same period of previous year”
Nilima Prasad Divi, page 6 of the filed PDF · View the filing
Standalone total income: ₹3,037 crores (Q1 FY27)
p. 6
“the total income of the quarter was ₹3,037 crores compared with ₹2,476 crores in the corresponding quarter of previous financial year”
Nilima Prasad Divi, page 6 of the filed PDF · View the filing
Standalone profit after tax: ₹891 crores (Q1 FY27)
p. 6
“profit after tax increased to ₹891 crores from ₹557 crores”
Nilima Prasad Divi, page 6 of the filed PDF · View the filing
Standalone revenue growth (constant currency): 10% (Q1 FY27)
p. 6
“On a constant currency basis, the standalone revenue recorded a growth of 10% during the quarter.”
Nilima Prasad Divi, page 6 of the filed PDF · View the filing
Exports share of standalone revenue: approximately 90% (Q1 FY27)
p. 6
“Exports continued to account for approximately 90% of the standalone revenue.”
Nilima Prasad Divi, page 6 of the filed PDF · View the filing
Custom Synthesis share of revenue: 60% (Q1 FY27)
p. 6
“The business mix for the quarter reflected Custom Synthesis contributing 60% of the revenue and Generics accounting for 40%, respectively.”
Nilima Prasad Divi, page 6 of the filed PDF · View the filing
Net material consumption: 31.2% of revenue (Q1 FY27)
p. 6
“Net material consumption for the quarter was 31.2% of the revenue from operations on a standalone basis, reflecting the continued benefits of our integrated manufacturing model and product mix.”
Nilima Prasad Divi, page 6 of the filed PDF · View the filing
Net forex loss: ₹7 crores (Q1 FY27)
p. 6
“the forex movements resulted in a net forex loss of ₹7 crores compared with a net gain of ₹39 crores in the corresponding quarter of the previous financial year”
Nilima Prasad Divi, page 6 of the filed PDF · View the filing
Global nutraceutical business revenue: ₹298 crores (Q1 FY27)
p. 6
“Our global nutraceutical business reported a revenue of ₹298 crores compared with ₹250 crores in the corresponding quarter of last year.”
Nilima Prasad Divi, page 6 of the filed PDF · View the filing
Capital work in progress: ₹2,034 crores (as of June 30, 2026)
p. 7
“capital work in progress stood at ₹2,034 crores as of June 30, 2026, reflecting the continuous progress of our ongoing expansion projects”
Nilima Prasad Divi, page 7 of the filed PDF · View the filing
Cash and cash equivalents: ₹3,611 crores (as of June 30, 2026)
p. 7
“cash and cash equivalents stood at ₹3,611 crores, trade receivables were ₹3,056 crores and inventory stood at ₹4,413 crores”
Nilima Prasad Divi, page 7 of the filed PDF · View the filing
Unit utilization across three units: 85% (Q1 FY27)
p. 11
“Around 85%, I would say, across all the 3 units.”
Nilima Prasad Divi, page 11 of the filed PDF · View the filing
Gross margin: approximately 68% (Q1 FY27)
p. 15
“It's going to be close to 68% this quarter approximately.”
Nilima Prasad Divi, page 15 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Custom Synthesis / overall revenue growth — double-digit growth · FY27
stated firmly by Dr. Kiran S. Divi
p. 12
“I would like to stick to my statement saying that we will show double-digit growth no matter what.”
Dr. Kiran S. Divi, page 12 of the filed PDF · View the filing
Overall revenue growth model — double-digit growth
stated as an aspiration by Nilima Prasad Divi
p. 13
“if you want to look at a revenue projection, we are looking at double-digit growth.”
Nilima Prasad Divi, page 13 of the filed PDF · View the filing
Generic portfolio commercial volumes for new DMF products — commercial volumes to move out · next 3 to 6 months
stated conditionally by Dr. Kiran S. Divi
p. 10
“once the qualification is done, we are expecting in the next 3 to 6 months, only commercial volumes will move out.”
Dr. Kiran S. Divi, page 10 of the filed PDF · View the filing
Iodine-based contrast media commercialization — start commercialization with second customer · next few months
stated firmly by Dr. Kiran S. Divi
p. 16
“The second one, we will start in the next few months.”
Dr. Kiran S. Divi, page 16 of the filed PDF · View the filing
Peptide segment ambition — largest integrated player
stated as an aspiration by Dr. Kiran S. Divi
p. 14
“we want to be the largest integrated player.”
Dr. Kiran S. Divi, page 14 of the filed PDF · View the filing
Custom Synthesis mix ratio — depends on regulatory approvals
stated conditionally by Dr. Kiran S. Divi
p. 15
“Everything depends on once we finish the validation, how the validation is ongoing right now. If the approvals come faster, then things will change.”
Dr. Kiran S. Divi, page 15 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said validations are ongoing and some product has been shipped, but declined to quantify due to CDAs.
Answered by Dr. Kiran S. Divi
Asked by Kunal Dhamesh: Whether the custom synthesis uptick includes dedicated capex project volumes yet.
p. 7
“It is hard to define that because like I said, we are undergoing validation of some of the capex projects. So a certain amount of product has also been shipped to the customer.”
Dr. Kiran S. Divi, page 7 of the filed PDF · View the filing
Management said regulatory clearances will be required and they are ready for inspections, with more clarity once customers file.
Answered by Dr. Kiran S. Divi
Asked by Surya Narayan Patra: What key milestones remain before commercial supply of dedicated projects begins.
p. 9
“we are completely ready for all regulatory submissions. We are ready for inspection anytime if there is an inspection.”
Dr. Kiran S. Divi, page 9 of the filed PDF · View the filing
Management said margins should be viewed on a yearly rather than quarterly basis due to business mix lumpiness.
Answered by Nilima Prasad Divi
Asked by Surya Narayan Patra: How margin trajectory looks given INR depreciation and raw material cost increases.
p. 9
“we always look at year-on-year basis rather than just a quarter.”
Nilima Prasad Divi, page 9 of the filed PDF · View the filing
Management attributed it to a deliberate three-month rolling inventory buildup and materials tied to new capex validation batches.
Answered by Nilima Prasad Divi
Asked by Damayanti Kerai: What drove the large increase in change in inventory this quarter versus prior periods.
p. 10
“we are currently stocking it on a 3 monthly basis. Like any given point of day for the next 3 months, are we secured for our production.”
Nilima Prasad Divi, page 10 of the filed PDF · View the filing
Management said Kakinada supports backward integration and pre-chemistry work, with long-term plans to qualify it for regulatory approval.
Answered by Dr. Kiran S. Divi
Asked by Damayanti Kerai: What role does Unit 3 (Kakinada) play in the supply chain.
p. 11
“Kakinada right now is playing a key role by doing our backward integrated work because we have several projects online, either with innovators or in-house generic molecules where we need additional capacity”
Dr. Kiran S. Divi, page 11 of the filed PDF · View the filing
Management said price increases reflect raw material cost pass-through rather than a market correction in pricing pressure.
Answered by Dr. Kiran S. Divi
Asked by Shyam Srinivasan: Are there signs the long generic pricing pressure cycle is ending given industry pricing inflection.
p. 11
“whatever you're seeing right now is a market correction based on the raw material prices that have taken a substantial hit. It's not based on the markets have corrected and the pricing pressure has gone down.”
Dr. Kiran S. Divi, page 11 of the filed PDF · View the filing
Management said gross margin was around 60% over the full year historically and expects growth trends to remain but declined to confirm quarter-level consistency.
Answered by Nilima Prasad Divi
Asked by Bino Pathiparampil: How will full-year gross and EBITDA margins compare to last year given quarterly lumpiness.
p. 15
“At gross level, I would say it was approximately 60% all over the year.”
Nilima Prasad Divi, page 15 of the filed PDF · View the filing
Management said the inventory change reflects both higher production volumes from validation projects and higher raw material costs, not solely a margin pressure signal.
Answered by Nilima Prasad Divi
Asked by Rahul Jeewani: Whether adjusting for the unusually large inventory change this quarter implies lower underlying gross and EBITDA margins.
p. 18
“There is also work in progress, there is intermediates, there are finished products. So it's a combination of all those that you are seeing here, along with the increase in the prices of the materials.”
Nilima Prasad Divi, page 18 of the filed PDF · View the filing
Management said this depends heavily on unpredictable Middle East macro conditions affecting solvent costs and inventory levels.
Answered by Nilima Prasad Divi
Asked by Rahul Jeewani: What level of inventory change should be expected for the rest of FY27.
p. 18
“It's a very difficult question to answer considering the -- what's happening in Middle East currently.”
Nilima Prasad Divi, page 18 of the filed PDF · View the filing
Risks flagged
Elevated and volatile solvent costs linked to Middle East geopolitical situation.
p. 5
“solvent costs remain elevated for a significant part of the period”
Nilima Prasad Divi, page 5 of the filed PDF · View the filing
Geopolitical uncertainty in West Asia affecting global supply chains.
p. 5
“the evolving geopolitical situation in West Asia has introduced additional uncertainty into global supply chain”
Nilima Prasad Divi, page 5 of the filed PDF · View the filing
Elevated freight rates and port congestion affecting export logistics.
p. 6
“Freight rates across both ocean and air transportation remained elevated while the availability of containers and ISO tanks continued to require careful planning and coordination.”
Nilima Prasad Divi, page 6 of the filed PDF · View the filing
Logistics disruptions including port congestion, cargo rollover and blank sailing.
p. 6
“International supply chain experienced congestion at several ports, tighter vessel allocation, cargo rollover, blank sailing and extended transit times, all of which increased operational complexities across export logistics.”
Nilima Prasad Divi, page 6 of the filed PDF · View the filing
Uncertainty over solvent supply and pricing tied to unpredictable Middle East conditions.
p. 14
“it is not something in our hands, because it is -- it comes in bulk and affects the entire country the same way.”
Nilima Prasad Divi, page 14 of the filed PDF · View the filing
Regulatory approval timelines for new custom synthesis projects remain uncertain.
p. 11
“every regulatory clearance also takes time even after you validate a certain new project, FDA will take its own time, 1 or 2 years since it’s a new place, and then they will qualify it.”
Dr. Kiran S. Divi, page 11 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.